Medical Management of the Dialysis Patient: Hypercalcemia
- Does this patient have hypercalcemia?
- What tests to perform?
- How should patients with hypercalcemia be managed?
- What happens to patients with hypercalcemia?
- How to utilize team care?
- Are there clinical practice guidelines to inform decision making?
Does this patient have hypercalcemia?
Key elements in the history
Diagnosed through routine labs
If severe may be associated with symptoms (see below)
Typically accompanied with other mineral metabolism abnormalities
May be a consequence or may be exacerbated by therapy used to treat disordered mineral metabolism
An indicator of severity of secondary hyperparathyroidism
Classic symptoms related to hypercalcemia include:
anxiety, depression, confusion, drowsiness, decreased level of consciousness
loss of appetite, nausea, constipation
Key signs and physical findings
Classic signs related to hypercalcemia include:
Shortened QT interval
Arrhythmias and bradycardia
Vascular, valvular and soft tissue calcification
Other diseases or syndromes with similar appearances
Recognize that other medical conditions could cause hypercalcemia in a dialysis patient, including
Controversies in the differential diagnosis
Kidney Disease Outcomes Quality Initiative: corrected total Ca levels should be maintained within the lower end of normal (8.4 - 9.5 mg/dl); hypercalcemia defined as corrected total calcium of > 10.2 mg/dl
Kidney Disease: Improving Global Outcomes: maintain Ca levels within the normal range
What tests to perform?
Which tests should I order?
Total calcium, serum albumin, intact PTH,serum phosphate
Ionized calcium may be helpful to confirm diagnosis
How do I interpret test results?
Kidney Disease Outcomes Quality Initiative: emphasis on corrected total calcium levels, and some consideration to calcium-phosphorus product
Kidney Disease: Improving Global Outcomes: trend more important than single values
How often should I order test?
Kidney Disease Outcomes Quality Initiative: every 3 months; more frequent (every month) with adjustments of therapy
Kidney Disease: Improving Global Outcomes: every 1-3 months; more frequent with adjustments of therapy
What are the next steps?
Response to therapeutic changes will determine next steps
If hypercalcemia is resistant to therapeutic changes and accompanied by severe hyperparathyroidism, parathyroidectomy may be indicated
If parathyroidectomy is being considered, imaging (sestamibi scan most sensitive) may be used to delineate parathyroid gland anatomy.
Overall Interpretation of test results
Diagnosis should be based on trend rather than single values, and consideration should be given to other mineral metabolites (Phosphate, PTH).
Prognosis dependent on initial or past response to therapy.
Controversies in diagnostic testing
Kidney Disease Outcomes Quality Initiative recommends stricter adherence to normal levels; allows use of active D only if levels of calcium are within the low normal range; also with some emphasis on calcium-phosphorus product
Kidney Disease: Improving Global Outcomes recommends a bit more lenient adherence to normal range and greater emphasis on overall trend rather than single abnormal values; importance of calcium-phosphorus product is deemphasized, though both calcium and phosphate levels should be monitored and both considered comprehensively when making therapeutic decisions
How should patients with hypercalcemia be managed?
Key treatment concepts
What to do first
Recognize that other reasons for hypercalcemia (outside of bone mineral metabolism disorders) could exist; ensure that these are ruled out
Kidney Disease Outcomes Quality Initiative: reduce dose Ca-based phosphate binders, or switch to non-calcium binder; discontinue vitamin D analogs until total corrected serum calcium returns to the target range (8.4 - 9.5 mg/dl)
Kidney Disease: Improving Global Outcomes: restrict dose of ca-based phosphate binders; and/or dose of vitamin D analog
Dialysate calcium adjustments:
Kidney Disease Outcomes Quality Initiative: if hypercalcemia persists, low dialysis calcium (1.5 to 2.0 mEq/L) should be used for 3-4 weeks
Kidney Disease: Improving Global Outcomes: general recommendation to maintain dialysate calcium between 2.5 to 3.0 mEq/L but not higher; provision for individualization of prescription for different patient. Dialysate calcium of 2.5 mEq/L thought to maintain neutral balance.
Surgical treatment, especially if accompanied by severe secondary hyperparathyroidism and resistant to treatment
Medical parathyroidectomy: cinacalcet may be tried prior to surgery
Severe hyperparathyroidism: as above
Calciphylaxis: if resistant to medical therapy, including cinacalcet, parathyroidectomy has been tried in some cases, especially if caciphylaxis is accompanied by severe hyperparathyroidism
Controversies in patient management
Due to insufficient knowledge on the state of calcium balance in a dialysis patient receiving therapy for mineral metabolism abnormalities, there are controversies as to the appropriate combination of available agents to use to manage the disorder. Some argue that it is best to prevent abnormalities in serum levels by using products that are less likely to cause hypercalcemia; while others argue that given the observational data that suggest survival benefit for vitamin D and any phosphate binders that less attention should be paid to serum levels. Possible combinations, without high-level evidence, are listed below.
low dialysis calcium bath and Ca-based phosphate binders
low dose vitamin D and Ca-based binders with cinacalcet (cinacalcet lowers calcium levels)
non-ca based binders with full dose vitamin D
Proponents of use of active vitamin D analogs suggest that it may not be appropriate to withhold vitamin D completely when serum calcium levels are elevated. They advocate use of lower dose of vitamin D analogs. In support of this approach is a recent meta-analysis that shows that serum calcium levels do not predict outcomes in patients with chronic kidney disease.
What happens to patients with hypercalcemia?
Natural history, anatomic and/or pathologic consequences, physiologic and/or pathophysiologic implications
PTH levels are tightly regulated by serum calcium
additional regulators include serum phosphate, calcitriol levels, FGF23
Genesis and maintenance of secondary hyperparathyroidism
Progressive CKD leads to increased FGF23 secretion, which in turn leads to suppressed calcitriol levels and secondary hyperparathyroidism
On dialysis, once secondary hyperparathyroidism is established disturbances in calcitriol, calcium and phosphate levels potently induce PTH secretion and parathyroid hyperplasia
On the cellular level, in CKD there is decreased expression of calcium sensing receptor, vitamin D receptor and fibroblast growth factor receptor and Klotho
once secondary hyperparathyroidism has been established, it is often accompanied by parathyroid hyperplasia
as a result, higher levels of serum calcium will be needed to suppress PTH release
this may lead to hypercalcemia
Autonomous parathyroid secretion
parathyroid hyperplasia may lead to autonomous secretion from individual nodules
Therapy with Vitamin D and Ca-based binders
These therapies are often associated with hypercalcemia, especially when the extra calcium load is not taken up by bone (such as in adynamic bone disease)
common in individuals with severe hyperparathyroidism
may be exacerbated by therapy with Vitamin D and Ca-based binders
Binders: Hypercalcemia more common with Ca-based binders compared to non-ca based binders
Active Vitamin D analogs: Newer non-calcemic analogs of Vitamin D developed to limit hypercalcemia, though hypercalcemia is still present
Cinacalcet: associated with hypocalcemia and typically requires co-treatment with calcemic agents
How to utilize team care?
Surgeons when considering parathyroidectomy
Assist in monitoring levels, response to therapy
May assist in ascertaining dietary calcium intake and instituting changes as needed
Are there clinical practice guidelines to inform decision making?
Listed above under individual sections
Main limitations for both sets of guidelines are:
Lack of detailed studies evaluating calcium balance in dialysis patients who are being treated with Ca-based binders and active vitamin D analog
Uncertainty regarding appropriate level of dietary calcium intake for dialysis patient
insufficient amount of patient-level outcomes data in the studies reviewed by both guidelines
What is the evidence?
Kumar, R, Thompson, JR. "The regulation of parathyroid hormone secretion and synthesis". JASN. vol. 22. 2011. pp. 216-224.(This article reviews the physiology of PTH hormone regulation in health and also describes the mechanisms for secondary hyperparathyroidism develoment in chronic kidney disease.)
Bazari, H, Jaff, MR, Mannstadt, M, Yan, S. "Case records of the Massachusetts General Hospital. Case 7-2007. A 59-year-old woman with diabetic renal disease and nonhealing skin ulcers". N Engl J Med. vol. 20; 356. 2007. pp. 1049-1057.(This clinical case presentation of calciphylaxis provides the differential diagnosis and reviews current clinical management strategies for this condition.)
Teng, M, Wolf, M, Lowrie, E, Ofsthun, MN, Lazarus, JM, Thadhani, R. "Survival in patients undergoing hemodialysis with paricalcitol or calcitriol therapy". N Engl J Med. vol. 349. 2003. pp. 446-456.(This observational study is one of many that demonstrate survival benefit with use of active vitamin D analogs in dialysis.)
Isakova, T, Gutierrez, OM, Chang, Y, Shah, A, Tamez, H, Smith, K, Thadhani, R, Wolf, M. "Phosphorus binders and survival on hemodialysis". JASN. vol. 20. 2009. pp. 388-396.(This observational study demonstrates survival benefit with use of phosphate binders in dialysis.)
Palmer, SC, Hayen, A, Macaskill, P, Pellegrini, F, Craig, JC, Elder, GJ, Strippoli, GF. JAMA. vol. 16;305. 2011 Mar. pp. 1119-27.(Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.This meta-analysis reports no association between serum calcium and the risk of death and cardiovascular events in chronic kidney disease.Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study.)
Fukagawa, M, Fukuma, S, Onishi, Y, Yamaguchi, T, Hasegawa, T, Akizawa, T, Kurokawa, K, Fukuhara, S. Clin J Am Soc Nephrol. vol. 7. 2012 Sep. pp. 1473-80.(This observational study reports on use of cinacalcet in the dialysis population and its effects on serum calcium levels.)
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|